A Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Locally Recurrent Prostate Cancer
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 12
- 主要终点
- Safety -Serious adverse events
研究概览
简要总结
This is a multi-center clinical study enrolling up to 12 participants . The primary objective of the study is to evaluate the safety of Alpha DaRT for the treatment of locally recurrent prostate cancer . The secondary objectives of the study is to evaluate the efficacy of the Alpha DaRT sources in locally recurrent prostate cancer patients assessed by biochemical and clinical evaluation of disease progression as well as overall survival
详细描述
This study will be a prospective, interventional, open label, single arm, multiple center study to assess the safety efficacy of Alpha DaRT . Eligible patients with Locally Recurrent Prostate Cancer will be categorized into the study.
The "Diffusing Alpha-emitter Radiation Therapy (DaRT)", based on the interstitial intratumoral placement of an encapsulated Radium-224 source (3.7 days half-life), is described in this study. These sources release short-lived alpha-emitting atoms into the tumor microenvironment by recoil. DaRT seeds will be inserted into the tumor according to a pre-determined plan.The delivery of the DaRT Sources into the prostate tumor is done by using the Alpha DaRT Alpha Prostate Applicator.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 120 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histologically and/or cytologically proven prostate adenocarcinoma
- •Biochemical recurrence by the Phoenix definition (PSA nadir + 2 ng/mL) and confirmed by a pre-treatment biopsy.
- •Patients eligible for focal salvage brachytherapy
- •Clinical stage T1-T2 on relapse; unilateral extracapsular extension (T3a) on MRI permitted except posteriorly relative to the rectum
- •Pre-salvage PSA level (rPSA) < 10 ng/ml
- •Target lesion is technically amenable for Alpha DaRT sources implantation.
- •Targetable lesion by either PSMA PET-CT according to PERCIST v1.0 OR by multiparametric MRI according RECIST v1.1 (Patients who were classified as stage II according to MRI)
- •Lesion size ≤ 5 cm in the longest diameter
- •ECOG Performance Status Scale 0 - 2
- •Life expectancy is more than 6 months
- •WBC ≥ 3500/µl, granulocyte ≥ 1500/µl
- •Platelet count ≥60,000/µl
- •Creatinine ≤1.9 mg/dL
- •AST and ALT ≤ 2.5 X upper limit of normal (ULN)
- •INR < 1.4 for patients not on Warfarin
- •Age ≥ 40 years old
- •Subjects are willing and able to sign an informed consent form
- •Patients must agree to use adequate contraception (vasectomy or barrier method of birth control) for 3 months after DaRT insertion
排除标准
- •Concomitant immunotherapy within the past 4 weeks.
- •Patients with lymph node or metastatic disease
- •Known hypersensitivity to any of the components of the treatment.
- •Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids.
- •Patients with prior surgery or low-dose-rate (LDR) brachytherapy as the primary treatment of their prostate cancer.
- •[For Stage 1 of the study only] Patients with prior high-dose-rate (HDR) brachytherapy or stereotactic body radiation therapy (SBRT) as the primary treatment of their prostate cancer.
- •Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 12 months.
- •Patients with uncontrolled intercurrent illnesses including, but not limited to an active infection requiring systemic therapy or a known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the trial or interfere with the study endpoints.
- •Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, low risk prostate cancer, or in situ cervical cancer.
- •Patient requires treatment not specified in this protocol which may conflict with the endpoints of this study including evaluation of response or toxicity of DaRT.
- •Patients do not agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation, and for 3 months after DaRT insertion
- •Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.
- •High probability of protocol non-compliance (in opinion of investigator).
研究组 & 干预措施
DaRT Seeds
Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
干预措施: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) (Device)
结局指标
主要结局
Safety -Serious adverse events
时间窗: From Day 0, Up to 3 years
The primary safety endpoint is the overall incidence of device related serious adverse events (SAEs) over the duration of the trial
次要结局
- To evaluate the efficacy of DaRT seeds according to blood tests(12 month study, 2 years follow up ±1 month every 6 months.)
- To evaluate the efficacy DaRT seeds according to Overall survival(once every 6 months for 2 years after final follow-up visit at 12 months)
- To evaluate the efficacy of DaRT seeds according to Life Questionnaire- QLQ- PR25(at day 0, 30 , 12 months and once every 6 months for 2 years)
- To evaluate the efficacy of DaRT seeds according to Life Questionnaire-IPSS(at day 0, 30 , 12 months and once every 6 months for 2 years)
- To evaluate the efficacy of DaRT seeds according to Life Questionnaire-SHIM(at day 0, 30 , 12 months and once every 6 months for 2 years)